Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer ; volume:199 ; number:1 ; day:10 ; month:3 ; year:2023 ; pages:91-98 ; date:5.2023
Breast cancer research and treatment ; 199, Heft 1 (10.3.2023), 91-98, 5.2023
- Creator
-
Taylor, Caitlin
Meisel, Jane
Foreman, Aimee J.
Russell, Christy
Bandyopadhyay, Dipankar
Deng, Xiaoyan
Floyd, Lisa
Zelnak, Amelia
Bear, Harry
O’Regan, Ruth
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-023-06890-7
- URN
-
urn:nbn:de:101:1-2023090510373333729274
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:56 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Taylor, Caitlin
- Meisel, Jane
- Foreman, Aimee J.
- Russell, Christy
- Bandyopadhyay, Dipankar
- Deng, Xiaoyan
- Floyd, Lisa
- Zelnak, Amelia
- Bear, Harry
- O’Regan, Ruth
- SpringerLink (Online service)
Other Objects (12)
Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
Rat Models of Hormone Receptor-Positive Breast Cancer
Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer
Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer
Update Breast Cancer 2022 part 3 – Early-stage breast cancer
Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Circulating Tumor Cells in Early-Stage Breast Cancer
An examination of health care utilization during the COVID-19 pandemic among women with early-stage hormone receptor-positive breast cancer
Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
Rat Models of Hormone Receptor-Positive Breast Cancer
Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer
Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer
Update Breast Cancer 2022 part 3 – Early-stage breast cancer
Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Circulating Tumor Cells in Early-Stage Breast Cancer
An examination of health care utilization during the COVID-19 pandemic among women with early-stage hormone receptor-positive breast cancer
Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
Rat Models of Hormone Receptor-Positive Breast Cancer
Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer
Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer
Update Breast Cancer 2022 part 3 – Early-stage breast cancer
Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Circulating Tumor Cells in Early-Stage Breast Cancer